Internal Medicine, Medical Oncology · East Brunswick, NJ
NPI
1467441352
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
629 Cranbury Rd Fl 2
East Brunswick, NJ, 08816
Phone (732) 390-7750
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
123,813 services
Medicare patients, 2024
688
Average age 76
Drug cost, 2024
$5.0M
2,610 prescriptions
Company payments, 2025
$144
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael J Nissenblatt was code J1439 (injection, ferric carboxymaltose, 1 mg), 33,000 times for 31 patients. In total Michael J Nissenblatt billed 123,813 services in 146 codes, and Medicare paid $2.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-15.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,000 | 31 | $0.87 | $29K |
| J0897 Injection, denosumab, 1 mg | Office | 6,120 | 45 | $20.45 | $125K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 3,828 | 17 | $20.51 | $79K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,050 | 12 | $35.75 | $109K |
| 36415 Venipuncture Blood Collection | Office | 1,177 | 420 | $8.64 | $10K |
| 99214 Office E&M - Established | Office | 960 | 412 | $111.48 | $107K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 920 | 30 | $0.09 | $83.22 |
| 96372 Injection Administration | Office | 458 | 142 | $12.79 | $5,860 |
| 85027 Blood Count | Office | 393 | 109 | $6.34 | $2,492 |
| 85025 Blood Count | Office | 373 | 109 | $7.61 | $2,839 |
| 99213 Office E&M - Established | Office | 332 | 238 | $79.04 | $26K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 259 | 122 | $14.35 | $3,718 |
| 99215 Office E&M - Established | Office | 257 | 135 | $163.18 | $42K |
| 96413 Chemotherapy Administration | Office | 231 | 66 | $123.03 | $28K |
| 96367 Intravenous Infusion, Hydration | Office | 205 | 53 | $26.50 | $5,433 |
By year: 2022 $1.5M for 90,367 services; 2023 $2.1M for 149,873 services; 2024 $2.3M for 123,813 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,177 | 420 | $8.64 | $10K |
| 85027 Blood Count | 393 | 109 | $6.34 | $2,492 |
| 85025 Blood Count | 373 | 109 | $7.61 | $2,839 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael J Nissenblatt prescribed most often to Medicare patients was Anastrozole, with 90 prescriptions and refills. In total Michael J Nissenblatt wrote 2,610 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 90 | 226 | 21 | $1,823 |
| Letrozole Generic | 88 | 216 | 25 | $2,221 |
| Prednisone Generic | 80 | 102 | 40 | $376 |
| Levothyroxine Sodium Generic | 79 | 215 | 22 | $1,008 |
| Eliquis Apixaban | 72 | 95 | 16 | $54K |
| Acyclovir Generic | 69 | 124 | 18 | $790 |
| Alprazolam Generic | 64 | 93 | 23 | $572 |
| Warfarin Sodium Generic | 55 | 123 | Under 11 | $799 |
| Furosemide Generic | 45 | 67 | 16 | $133 |
| Sertraline Hcl Generic | 41 | 117 | 12 | $535 |
| Tamoxifen Citrate Generic | 41 | 99 | Under 11 | $791 |
| Atorvastatin Calcium Generic | 40 | 82 | Under 11 | $479 |
| Pantoprazole Sodium Generic | 39 | 94 | 14 | $587 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 39 | 39 | 14 | $717 |
| Ondansetron Odt Ondansetron | 35 | 45 | 13 | $1,035 |
Brand drugs: 658 claims; generic drugs: 1,927 claims; opioid claims: 71.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael J Nissenblatt $144 ($144 in general payments such as food, travel and fees) from 5 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $49.43.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.